Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Ivo Radman"'
Autor:
Ida Hude Dragičević, Sandra Bašić-Kinda, Helena Markotić, Martina Morić-Perić, Dino Dujmović, Ivo Radman, Barbara Dreta, Snježana Dotlić, Ivana Ilić, Lea Galunić Bilić, Margareta Dobrenić, Marko Kralik, Igor Aurer
Publikováno v:
Medicina, Vol 60, Iss 3, p 430 (2024)
Background and Objectives: eBEACOPP is the most effective chemotherapy regimen for younger patients with early unfavorable (EU) and advanced-stage (AS) Hodgkin lymphoma (HL), albeit with significant toxicities. The 14-day/cycle prednisone course cont
Externí odkaz:
https://doaj.org/article/aa353efaeaa543cd9c08ecf8a014fba1
Autor:
Zrinka Sertić, Marko Lucijanić, Sandra Bašić-Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Božena Coha, Dražen Pulanić, Zinaida Perić, Lana Desnica, Mirta Mikulić, Marijo Vodanović, Ivo Radman-Livaja, Dragana Šegulja, Dunja Rogić, Toni Valković, Igor Aurer, Nadira Duraković
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2892 (2022)
Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1
Externí odkaz:
https://doaj.org/article/302bd8409cfa4283acb5a7c1a229e798
Autor:
Ida Hude Dragičević, Sandra Bašić-Kinda, Dino Dujmović, Ivo Radman, Barbara Dreta, Sandra Dotlić, Lea Galunić-Bilić, Margareta Dobrenić, Marko Kralik, Pavle Rončević, Igor Aurer
Publikováno v:
HemaSphere, Vol 6, Pp 8-8 (2022)
Externí odkaz:
https://doaj.org/article/cbf2c62b30d0467a8e3ae6b76a4ca891
Autor:
Nadira Duraković, Zinaida Perić, Sandra Bašić Kinda, Lana Desnica, Dino Dujmović, Ivo Radman Livaja, Ranka Serventi Seiwerth, Igor Aurer, Radovan Vrhovac
Publikováno v:
Clinical Hematology International, Vol 3, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/cd5db7e76ca04e8f809d3a388da93dd5
Publikováno v:
Haematologica, Vol 92, Iss 7 (2007)
We investigated the association of FcγRIIIa and FcγRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcγRIIIa and FcγRIIa polymorphisms did not influence response, event-free or overall survival.
Externí odkaz:
https://doaj.org/article/6b2d8186e106473695f422b2aacdd1d5
Autor:
Vedran Premužić, Sandra Bašić-Kinda, Ivo Radman, Dino Dujmović, Ivana Ilić, Neno Živković, Lucija Maleta, Marko Kralik, Margareta Dobrenić, Lea Galunić-Bilić, Pavle Rončević, Marijo Vodanović, Igor Aurer
Publikováno v:
Medicine. 102:e33675
Autor:
Inga Mandac-Rogulj, Duška Petranović, Marijo Vodanović, Jelena Roganović, Vlatko Pejša, Toni Valković, Ivo Radman, Igor Aurer, Slobodanka Ostojić Kolonić, Rajko Kusec
Publikováno v:
Liječnički vjesnik. 141:1-13
Iron deficiency anemia (IDA) is an important public health problem. Almost 30% of the world’s population (> 2 billion) has iron deficiency (ID) with or without anemia. Treatment of IDA requires teamwork. It is important to treat anemia and the unde
Autor:
Ranka Serventi Seiwerth, Martina Moric Peric, Alen Ostojić, Vlatka Periša, Pavle Rončević, Ines Bojanić, Nadira Duraković, Igor Aurer, Goran Rinčić, Sandra Bašić-Kinda, Ivana Budisavljević, Marijo Vodanović, Ivo Radman, Silva Zupančić-Šalek, Vedrana Gačić, Dominik Lozić, Dubravka Sertić, Ivan Zekanović
Publikováno v:
Liječnički vjesnik. 140:303-306
Autor:
Zinaida Peric, Nadira Duraković, Lana Desnica, Igor Aurer, Ivo Radman Livaja, Ranka Serventi Seiwerth, Dino Dujmović, Sandra Bašić Kinda, Radovan Vrhovac
Publikováno v:
Clinical Hematology International
Clinical Hematology International, Vol 3, Iss 3 (2021)
Clinical Hematology International, Vol 3, Iss 3 (2021)
Ishod alotransplantacije u Hodgkinovom limfomu ovisno o odgovoru na prethodno liječenje
Autor:
Klara Dubravčić, Igor Aurer, Martina Bogeljic-Patekar, Slobodanka Ostojić-Kolonić, Ivana Franic-Šimic, Sandra Bašić-Kinda, Vlatko Pejša, Ozren Jakšić, Ida Hude, Ena Ranković, Ivo Radman
Publikováno v:
Journal of Cancer Science and Clinical Therapeutics.
Due to age and comorbidities many patients with CLL receive chlorambucil as front-line treatment. Doses and schedules of this drug vary widely but it is not clear whether this affects outcomes. We performed this retrospective analysis to compare the